Discover strategies for effective thyroid health to optimize hormone levels and take control of your health journey today.

Abstract

In this educational post, I walk you through my approach to hormone health through a systems-biology lens and how integrative chiropractic care fits seamlessly into a whole-person treatment plan. I explain why relying solely on population-based “normal ranges” for hormones like testosterone and thyroid markers can miss the mark for individual patients. I discuss the interconnectedness of the hypothalamic-pituitary-adrenal-gonadal-thyroid axis, how symptoms and clinical context guide the selection of safe, personalized targets, and why we avoid “treating numbers” in isolation. You will learn how I use evidence-based protocols for testosterone, thyroid support (including T4 and T3 considerations), iodine, progesterone, and the nuanced decision-making around estrogen in women with a history of breast cancer—balancing symptom relief, quality of life, and risk. I also show how integrative chiropractic care enhances autonomic regulation, improves lymphatic and venous return, and helps normalize neuroendocrine function, thereby supporting hormone therapies. Along the way, I share clinical observations from my practice and highlight recent research methods and findings that inform these strategies. By the end, you will understand the physiological” why” behind each decision, how we set initial therapeutic ranges and then individualize, and why collaborative, patient-centered care consistently leads to better outcomes.

Personalized Hormone Targets: Beyond One-Size-Fits-All Normal Ranges

When patients ask me, “What is the normal range?” I respond with a focus on the person, not the population. Population reference intervals are useful for screening for extremes, but they are not optimized for every individual. The same lab value can be health-preserving in one person and risk-elevating in another, depending on age, comorbidities, and physiology.

• The problem with one-size-fits-all:

• • Reference ranges are derived from broad populations with different ages, health states, lifestyles, and genetics.
  • Some ranges include individuals with undiagnosed metabolic or inflammatory conditions, skewing what “normal” looks like.
  • Hormone receptors and downstream signaling exhibit nonlinear dynamics; symptom expression does not align perfectly with serum concentration.

I often set an initial goal range to begin therapy—especially for hormones like testosterone—because we need a safe, evidence-informed starting point. From there, we calibrate to the patient’s physiology and lived experience. For example, a man with a total testosterone level of around 300 ng/dL might feel “fine,” but evidence links low testosterone to higher all-cause mortality, cardiometabolic risk, cognitive decline, and adverse body composition trends (Corona et al., 2018; Huo et al., 2016). The receptors are unlikely to be saturated at 300, and tissue-level androgen action may be insufficient even if mood seems stable.

• Why initial target ranges matter:

• • They anchor clinical decision-making while we track objective outcomes and subjective improvements.
  • They reduce the risk of under-treating or over-treating early on.
  • They allow us to apply published risk thresholds and individualize care based on the patient’s symptoms, goals, and tolerance.

In practice, once symptoms improve and biomarkers stabilize, I individualize away from the initial target based on function, safety labs, body composition, sleep quality, cardiometabolic markers, and cognitive performance. This “target then tailor” approach reflects the reality that normal is not optimal—and optimal is personal (Bhasin et al., 2018).

Citations:

• Bhasin, S., et al. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-00229
• Corona, G., et al. (2018). Does low testosterone syndrome protect against metabolic syndrome? The Journal of Sexual Medicine. https://doi.org/10.1016/j.jsxm.2018.02.010
• Huo, S., et al. (2016). Association of testosterone and mortality in men. European Journal of Endocrinology. https://doi.org/10.1530/EJE-16-0071

The Neuroendocrine Symphony: Integrating Testosterone, Thyroid, And Cortisol

Patients rarely have a single hormone out of balance. The hypothalamic-pituitary-adrenal-gonadal-thyroid (HPAGT) network is an interconnected system in which adjustments in one node influence the others.

• Key interactions:

• • Cortisol excess blunts GnRH and LH secretion, lowering testosterone; chronic stress also reduces thyroid hormone conversion from T4 to T3 by upregulating deiodinase 3 and increasing reverse T3 (rT3).
  • Thyroid hormone influences sex hormone-binding globulin (SHBG), thereby changing free testosterone availability.
  • Insulin resistance and visceral adiposity increase aromatase activity, converting testosterone to estradiol and suppressing gonadal output.

Physiology in brief:

• Testosterone’s effects on mitochondria and skeletal muscle improve insulin sensitivity and reduce visceral fat, thereby lowering inflammatory cytokines (TNF-?, IL-6) that otherwise impair thyroid deiodination (Grossmann, 2018).
• Adequate T3 within cells supports mitochondrial biogenesis and beta-oxidation, impacting energy, mood, and thermogenesis.
• Balanced cortisol rhythms stabilize the HPT and HPG axes; disordered sleep or chronic inflammation perturbs this balance.

In the clinic, when someone feels “normal” with suboptimal numbers, I assess:

• Diurnal cortisol pattern and sleep architecture.
• Thyroid panel including TSH, free T4, free T3, and—selectively—reverse T3.
• Body composition, VO2 max trends, and fasting insulin/HOMA-IR.
• Symptoms: libido, mood, recovery, cognition, thermoregulation, and bowel rhythm.

This systems approach prevents the common pitfall of “fixing” testosterone without addressing the thyroid or adrenal context that may be driving the symptoms in the first place.

Citation:

• Grossmann, M. (2018). Hypogonadism and male obesity: Focus on unresolved questions. Clinical Endocrinology. https://doi.org/10.1111/cen.13690

Thyroid Therapy Rationale: T4, T3, And Why Stability Matters

I routinely encounter patients whose symptoms persist despite a “normal” TSH or a standard-dose levothyroxine (T4) prescription. The central issue: T4 is a prohormone that requires peripheral conversion to T3, the bioactive hormone that acts at the nuclear thyroid receptor. While T4 provides pharmacokinetic stability with a long half-life and steady serum levels, some patients struggle with conversion due to inflammation, nutrient deficiencies (selenium, zinc, iron), liver dysfunction, or high cortisol. In these cases, symptoms such as fatigue, cold intolerance, constipation, hair loss, and cognitive fog persist.

• Why use T4:

• • Stability: Its ~7-day half-life smooths dosing gaps and supports consistent tissue exposure.
  • Safety: Wide clinical experience and guideline support make it first-line for overt hypothyroidism.

• Why consider T3 (liothyronine) or combination therapy:

• • Conversion issues: Low free T3 or high reverse T3 suggest impaired deiodination.
  • Symptom persistence: If symptoms persist after optimizing T4 and addressing nutrient and stress factors, small, divided doses of T3 can restore euthyroid function at the tissue level.
  • Physiologic profiles: Some patients report improved mood, energy, and thermogenesis on T4/T3 combinations, supported by select RCTs and mechanistic data (Escobar-Morreale et al., 2005; Hoang et al., 2013).

In practice, I may trial very low-dose T3 (e.g., 2.5–5 mcg, once or twice daily), then titrate slowly while closely monitoring heart rate, blood pressure, sleep, anxiety, and labs. We prioritize cardiac safety and seek convergence of subjective and objective findings before making further adjustments.

• Pregnancy special case:

• • During the first 18 weeks of gestation, the fetus relies on maternal T4 crossing the placenta to synthesize T3 in fetal tissues. For this reason, even in combination regimens, I ensure adequate T4 support during early pregnancy to protect fetal neurodevelopment (Alexander et al., 2017).

Citations:

• Alexander, E. K., et al. (2017). 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. https://doi.org/10.1089/thy.2016.0457
• Escobar-Morreale, H. F., et al. (2005). Replacement therapy for hypothyroidism with combinations of levothyroxine plus liothyronine. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-0189
• Hoang, T. D., et al. (2013). Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-4104

Cracking The Low Thyroid Code- Video

Iodine, Nutrients, And The Thyroid: Precision Over Guesswork

Iodine remains a critical substrate for thyroid hormone synthesis, but more is not always better. In my earlier years, I checked iodine frequently; over time, I have refined my approach.

• Physiology:

• • Iodine and tyrosine form the backbone of T4 and T3. Thyroid peroxidase (TPO) catalyzes iodination; excess iodine can trigger the Wolff-Chaikoff effect, temporarily suppressing thyroid hormone synthesis to protect against hyperthyroidism.
  • Selenium is required for deiodinase activity (conversion of T4 to T3) and for glutathione peroxidase to quell oxidative stress within the thyroid follicle.

• Clinical strategy:

• • I evaluate dietary history, prior iodine exposure, autoimmune markers (TPOAb, TgAb), and urinary iodine only when it will change management.
  • I avoid aggressive iodine supplementation in autoimmune thyroid disease and focus on balanced intake (typically through iodized salt, seafood, or carefully dosed supplements).
  • I correct cofactors: selenium (100–200 mcg/day), iron sufficiency, zinc, vitamin A and D, and manage gut dysbiosis that impairs nutrient absorption.

The goal is to respect the thyroid’s delicate redox environment—supporting hormone synthesis and conversion without provoking autoimmunity or functional suppression (Zimmermann & Boelaert, 2015).

Citation:

• Zimmermann, M. B., & Boelaert, K. (2015). Iodine deficiency and thyroid disorders. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(14)70225-6

Progesterone, Estrogen, And Oncologic Context: Navigating Risk And Quality Of Life

Hormone therapy in patients with a history of breast cancer is complex. In my clinical practice, I prioritize safety, informed consent, and shared decision-making. There are clear distinctions among progesterone, progestins, androgens, and estrogens, and each carries a different risk profile.

• What we can generally support:

• • Progesterone (bioidentical micronized) is often usable across a spectrum of oncologic histories to support sleep, anxiety modulation (via GABA-A receptor effects), and genitourinary symptoms. It does not share the same risk profile as synthetic progestins used in older trials (e.g., medroxyprogesterone acetate in WHI) (Stute et al., 2016).
  • Testosterone in women, at physiologic doses, can improve libido, energy, and musculoskeletal health; observational data and mechanistic insights suggest neutral or favorable effects on breast tissue proliferation when properly dosed and monitored, though the evidence remains heterogeneous (Glaser & Dimitrakakis, 2013).
  • Thyroid and adrenal support are generally safe and necessary when indicated, regardless of oncologic history.

• Estrogen: a nuanced decision

• • The decision to use estradiol depends on tumor receptor status, stage, time since treatment, type of surgical intervention (e.g., bilateral mastectomy), and patient values.
  • For women with a remote, low-stage history who are suffering severely (vulvovaginal atrophy, recurrent UTIs, insomnia, bone loss, cardiovascular risk acceleration), low-dose, local vaginal estrogen or carefully titrated systemic therapy may be considered after an informed risk-benefit discussion and, ideally, with oncologic collaboration. There is growing literature supporting the safety of local therapies in many breast cancer survivors, though practice patterns vary (Santen et al., 2020).

• Practical approach I use:

• • Start with non-estrogenic strategies: pelvic floor therapy, vaginal DHEA, lubricants/moisturizers, and physiologic testosterone with or without progesterone.
  • If symptoms remain debilitating, revisit the conversation with updated data, clarify goals, document shared decision-making, and implement tight monitoring.
  • Keep estradiol at the lowest effective dose; in some cases, serum estradiol targets remain very low or near assay limits, especially if a patient is on aromatase inhibitors, while focusing on symptom relief and tissue health.

Ultimately, the ethical imperative is to respect the patient’s autonomy and quality of life while maintaining medical vigilance. I have cared for many women who, after years of debilitating symptoms and recurrent infections, elected low-dose local or systemic therapy with substantial improvement in daily function, intimacy, and sleep—outcomes that meaningfully influence long-term cardiometabolic and cognitive health.

Citations:

• Glaser, R., & Dimitrakakis, C. (2013). Testosterone therapy in women: Myths and misconceptions. Maturitas. https://doi.org/10.1016/j.maturitas.2013.01.006
• Santen, R. J., et al. (2020). Managing menopausal symptoms and associated clinical issues in breast cancer survivors. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa104
• Stute, P., et al. (2016). Bioidentical hormones for menopausal symptoms: An update. Climacteric. https://doi.org/10.1080/13697137.2016.1192339

Integrative Chiropractic Care: Aligning The Spine, Calming The Axis, Supporting Hormones

As a chiropractor and family nurse practitioner, I see daily how musculoskeletal alignment and autonomic regulation influence endocrine outcomes. Integrative chiropractic care is a cornerstone in my hormone protocols because it optimizes the neurovascular pathways that hormones depend on.

• Mechanisms linking chiropractic care to endocrine balance:

• • Autonomic nervous system (ANS) modulation: Dysfunction in the high thoracic and cervical regions can perpetuate sympathetic overdrive, elevating cortisol and inhibiting thyroid hormone conversion. Gentle spinal adjustments, soft tissue release, and breathing retraining rebalance sympathetic-parasympathetic tone, measured by improvements in heart rate variability (HRV).
  • Lymphatic and venous return: Rib cage mobility, diaphragmatic function, and thoracic pump mechanics support lymph flow and clearance of inflammatory cytokines that interfere with hormone signaling.
  • Pain reduction and sleep improvement: Lowering nociceptive input reduces HPA axis hyperactivity, normalizing cortisol rhythms and improving growth hormone pulses, which aid tissue repair and metabolic health.

• What I typically include:

• • Targeted cervical and thoracic adjustments to reduce sympathetic overflow.
  • Myofascial release for scalenes, pectorals, suboccipitals, and diaphragm to improve breathing mechanics.
  • Vagus nerve-supportive breathwork (slow 4-6 breaths per minute) and biofeedback to improve HRV.
  • Gait assessment and pelvic alignment to reduce systemic pain load, which otherwise fuels stress hormones.
  • Exercise prescriptions: resistance training 2–4 times weekly for anabolic signaling; zone 2 aerobic training to improve mitochondrial density and insulin sensitivity.

My clinical observations, documented across years of patient care, show that when I integrate these chiropractic and rehabilitative strategies with endocrine therapies, patients stabilize faster and need fewer medication adjustments. I detail many of these observations through my practice resources and case narratives (Jimenez, n.d.-a; Jimenez, n.d.-b).

References:

• Jimenez, A. (n.d.-a). Personal Injury Doctor Group. https://personalinjurydoctorgroup.com/
• Jimenez, A. (n.d.-b). LinkedIn profile. https://www.linkedin.com/in/dralexjimenez/

Why We Do Not Treat Numbers: Data-Informed, Symptom-Led Care

I embrace lab data and modern imaging, but I do not reduce care to a spreadsheet. Patients are people with complex lives. Hormones interact with sleep, pain, trauma history, nutrition, and movement patterns. My method is to let the data inform the plan while letting the patient’s function and quality of life shape the final path.

• Guardrails I use:

• • Establish an evidence-based initial range for key hormones (testosterone and thyroid hormones) to minimize risk.
  • Layer lifestyle and chiropractic interventions to normalize autonomic tone and inflammation.
  • Titrate therapy based on symptom scores, HRV, sleep metrics, and body composition—not just a lab threshold.
  • Reassess every 8–12 weeks to ensure we are progressing toward durable, stable wellness.

This iterative approach respects the fact that hormonal physiology is dynamic and patient needs evolve.

Clinical Scenarios: Applying The Principles

• The “normal but not optimal” male:

• • A man presents with total testosterone at 300–350 ng/dL, “feels okay,” but has central adiposity, elevated triglycerides, low HRV, and fragmented sleep. We improve sleep timing and nasal breathing, adjust C/T spine mechanics, and reduce sympathetic tone. We address insulin resistance with resistance training and nutrition. If symptoms persist, we initiate testosterone therapy, aiming first for an evidence-informed range, then fine-tune to the level at which his cognition, libido, and recovery normalize. Over months, triglycerides drop, visceral fat reduces, and HRV improves—benefits likely unattainable by numbers alone.

• The persistent hypothyroid patient:

• • A woman on T4 with normal TSH still has fatigue and cold intolerance. Her free T3 is low-normal with elevated rT3, ferritin is suboptimal, selenium intake is low, and she is under significant stress. We correct iron and selenium, implement parasympathetic supports (breathing, cervical/thoracic mobilization), and add a microdose of T3 in divided doses. Within 8–12 weeks, her resting energy expenditure, mood, and bowel rhythm improve. We maintain T4 sufficiency, especially if she becomes pregnant, to support fetal neurodevelopment.

• Breast cancer survivor with severe genitourinary symptoms:

• • A survivor, years post-stage 1 disease and definitive surgery, is incapacitated by recurrent UTIs, vaginal atrophy, insomnia, and marital strain. We start with progesterone for sleep, physiologic testosterone, pelvic floor therapy, and local nonhormonal moisturizers. If inadequate, we consider local vaginal estrogen or DHEA, with input from the oncologist, carefully monitoring symptoms, serum levels when appropriate, and recurrence risk. Quality-of-life restoration lowers stress hormones and improves cardiometabolic markers, which are themselves vital determinants of long-term survival.

These cases reflect a guiding principle: align endocrine therapy with nervous system regulation and patient values to create sustainable outcomes.

Safety First: Monitoring, Dosing, And When To Pause

• Testosterone:

• • Monitor hematocrit/hemoglobin, PSA (for men), lipids, liver enzymes, and estradiol/aromatization. Optimize the dose and route of delivery (e.g., transdermal vs. injectable) to balance peaks and troughs. Incorporate lifestyle measures to minimize aromatase activity.

• Thyroid:

• • Recheck TSH, free T4/T3, and symptoms 6–8 weeks after any dose change. Watch for signs of overtreatment: palpitations, insomnia, anxiety, low TSH with high free T3. Pay special attention in pregnancy to maintain adequate T4.

• Progesterone and estrogen:

• • Match formulation to goals. Micronized progesterone is often best tolerated at night. For estrogen, use the lowest effective dose and route consistent with risk profile (transdermal is often preferred for thrombotic risk). Coordinate with oncology when appropriate.

• Iodine and nutrients:

• • Avoid blind high-dose iodine. Test and correct cofactors that influence conversion and receptor function. Address gut and liver health to support clearance and hormone recycling.

Safety does not mean paralysis. It means structured progress with measurable checkpoints, always centered on the patient’s well-being.

Evidence-Informed, Human-Centered Care: What The Data And Patients Tell Us

Modern, evidence-based practice is not constrained to RCTs alone; it integrates high-quality trials, mechanistic studies, cohort data, and real-world outcomes. We use validated instruments—symptom questionnaires, HRV, actigraphy sleep data, body composition scans—and pair them with labs to triangulate progress.

• Why this approach works:

• • Biomarkers catch risk earlier; symptoms capture lived biology.
  • Chiropractic and rehabilitative care change inputs at the level of the nervous system, improving downstream endocrine resilience.
  • Individualized dosing acknowledges receptor pharmacodynamics and genetic variability in enzyme function (e.g., deiodinases, aromatase).

My ongoing clinical work and patient outcomes echo what I share on my platforms: when we align spine, breath, sleep, movement, and hormones, we get compounding benefits that endure (Jimenez, n.d.-a; Jimenez, n.d.-b).

Practical Takeaways For Patients And Clinicians

• Key principles:

• • Use lab ranges as starting points, not finish lines.
  • Treat people, not numbers, and measure both symptoms and biomarkers.
  • Stabilize the autonomic nervous system through integrative chiropractic methods to support endocrine balance.
  • When hypothyroid symptoms persist on T4, investigate conversion and consider cautious T3 addition with nutrient optimization.
  • In oncologic contexts, separate progesterone from progestins, use testosterone judiciously, and approach estrogen with individualized risk assessment and shared decision-making.
  • During early pregnancy, ensure adequate T4 to support fetal brain development.

• Why these work:

• • They align care with biology: hormones are signals in a network, not isolated levers.
  • They leverage the body’s capacity to heal by reducing mechanical, inflammatory, and stress burdens.
  • They honor the patient’s goals and autonomy, which sustains adherence and lifestyle transformation.

Closing Perspective

My commitment is to bring you the latest findings from leading researchers and to apply them through modern, evidence-based methods that respect your individuality. Integrative chiropractic care is not an add-on; it is a foundational strategy that makes hormone therapies more effective and sustainable. With careful monitoring, shared decision-making, and an understanding of physiology, we can move beyond generic normal ranges toward personal optimization—one that improves how you feel today and how you thrive for decades.

References

• Alexander, E. K., et al. (2017). 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid
• Bhasin, S., et al. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism
• Corona, G., et al. (2018). Does low testosterone syndrome protect against metabolic syndrome? The Journal of Sexual Medicine
• Escobar-Morreale, H. F., et al. (2005). Replacement therapy for hypothyroidism with combinations of levothyroxine plus liothyronine. The Journal of Clinical Endocrinology & Metabolism
• Glaser, R., & Dimitrakakis, C. (2013). Testosterone therapy in women: Myths and misconceptions. Maturitas
• Grossmann, M. (2018). Hypogonadism and male obesity: Focus on unresolved questions. Clinical Endocrinology
• Hoang, T. D., et al. (2013). Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism. The Journal of Clinical Endocrinology & Metabolism
• Jimenez, A. (n.d.-a). Personal Injury Doctor Group
• Jimenez, A. (n.d.-b). LinkedIn profile
• Huo, S., et al. (2016). Association of testosterone and mortality in men. European Journal of Endocrinology
• Santen, R. J., et al. (2020). Managing menopausal symptoms and associated clinical issues in breast cancer survivors. Journal of Clinical Endocrinology & Metabolism
• Stute, P., et al. (2016). Bioidentical hormones for menopausal symptoms: An update. Climacteric
• Zimmermann, M. B., & Boelaert, K. (2015). Iodine deficiency and thyroid disorders. The Lancet Diabetes & Endocrinology

SEO tags: integrative chiropractic care, hormone optimization, testosterone therapy, thyroid T4 T3, iodine and thyroid, progesterone safety, estrogen, autonomic nervous system and hormones, HRV and endocrine health, functional medicine hormones, musculoskeletal and hormones, patient-centered hormone care, Dr. Alexander Jimenez, evidence-based hormone therapy, neuroendocrine axis